Serum immune modulators during the first cycle of anti‐PD‐1 antibody therapy in non‐small cell lung cancer: Perforin as a biomarker

BACKGROUND: Currently used biomarkers for immunotherapy are inadequate because they are only based on tumor properties. In view of microenvironment changes by tumors, host immunity should be considered, which may result in identifying more accurate and easily detectable biomarkers for daily clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Ota, Takayo, Fukui, Tomoya, Nakahara, Yoshiro, Takeda, Takayuki, Uchino, Junji, Mouri, Takako, Kudo, Keita, Nakajima, Saki, Suzumura, Tomohiro, Fukuoka, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606020/
https://www.ncbi.nlm.nih.gov/pubmed/32915511
http://dx.doi.org/10.1111/1759-7714.13650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606020/
https://www.ncbi.nlm.nih.gov/pubmed/32915511
http://dx.doi.org/10.1111/1759-7714.13650

Ejemplares similares